Federated Hermes Inc. Reduces Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Posted by Defense World Staff on Mar 10th, 2023

Federated Hermes Inc. lessened its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR – Get Rating) by 1.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 605,795 shares of the company’s stock after selling 7,252 shares during the period. Federated Hermes Inc. owned 1.57% of Voyager Therapeutics worth $3,586,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 32.4% in the third quarter. Armistice Capital LLC now owns 3,396,000 shares of the company’s stock valued at $20,104,000 after acquiring an additional 832,000 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Voyager Therapeutics by 1,735.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 827,950 shares of the company’s stock worth $4,893,000 after purchasing an additional 782,850 shares during the period. Millennium Management LLC grew its holdings in shares of Voyager Therapeutics by 291.0% during the 2nd quarter. Millennium Management LLC now owns 828,796 shares of the company’s stock worth $4,898,000 after purchasing an additional 616,814 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Voyager Therapeutics during the 3rd quarter worth about $1,713,000. Finally, Walleye Capital LLC purchased a new stake in Voyager Therapeutics in the 1st quarter valued at about $1,148,000. Institutional investors and hedge funds own 59.58% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on VYGR. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 14th. Oppenheimer initiated coverage on shares of Voyager Therapeutics in a research report on Thursday. They set an “outperform” rating for the company.

Insider Buying and Selling at Voyager Therapeutics

In other news, major shareholder Rock Ventures Iii L.P. Third sold 128,642 shares of the stock in a transaction dated Wednesday, February 1st. The shares were sold at an average price of $9.32, for a total transaction of $1,198,943.44. Following the sale, the insider now owns 4,685,291 shares of the company’s stock, valued at $43,666,912.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, major shareholder Ecor1 Capital, Llc sold 110,000 shares of the business’s stock in a transaction on Wednesday, January 11th. The stock was sold at an average price of $8.50, for a total transaction of $935,000.00. Following the completion of the transaction, the insider now directly owns 3,851,507 shares of the company’s stock, valued at approximately $32,737,809.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Rock Ventures Iii L.P. Third sold 128,642 shares of the company’s stock in a transaction dated Wednesday, February 1st. The stock was sold at an average price of $9.32, for a total value of $1,198,943.44. Following the sale, the insider now owns 4,685,291 shares in the company, valued at approximately $43,666,912.12. The disclosure for this sale can be found here. Insiders sold a total of 1,035,636 shares of company stock valued at $8,724,631 in the last three months. 22.00% of the stock is owned by corporate insiders.

Voyager Therapeutics Stock Down 2.7 %

Shares of NASDAQ VYGR opened at $7.91 on Friday. Voyager Therapeutics, Inc. has a twelve month low of $4.61 and a twelve month high of $10.81. The stock has a fifty day simple moving average of $8.01 and a 200-day simple moving average of $6.61.

About Voyager Therapeutics

(Get Rating)

Voyager Therapeutics, Inc is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A.